Abstract
In a recent Nature article, Middleton et al. report the National Lung Matrix trial results where patients with previously treated non-small cell lung cancer (NSCLC) are assigned to personalized therapy based on the results of a 28-gene next-generation sequencing panel test.
| Original language | English |
|---|---|
| Pages (from-to) | 320-322 |
| Number of pages | 3 |
| Journal | Cancer Cell |
| Volume | 38 |
| Issue number | 3 |
| DOIs |
|
| State | Published - Sep 14 2020 |